BUPRENORPHINE pharmaceutical API fine chemical suppliers

Subscribe to access the full database, or Start Trial
Vendor	Vendor Homepage	Vendor Sku	API Url
Clearsynth	⤷ Start Trial	CS-O-00994	⤷ Start Trial
LGC Standards	⤷ Start Trial	LGCAMP0120.00-01	⤷ Start Trial
LGC Standards	⤷ Start Trial	LGCAMP0120.00-02	⤷ Start Trial
LGC Standards	⤷ Start Trial	LGCFOR0120.00	⤷ Start Trial
>Vendor	>Vendor Homepage	>Vendor Sku	>API Url

Last updated: February 19, 2026

This report analyzes the current landscape for sourcing bulk Active Pharmaceutical Ingredient (API) for buprenorphine. Key manufacturers, regulatory considerations, and market trends are examined to inform R&D and investment decisions.

Who are the Primary Manufacturers of Buprenorphine API?

The global supply of buprenorphine API is concentrated among a limited number of manufacturers, primarily located in Asia. These companies operate under strict regulatory oversight and are critical to the pharmaceutical supply chain for buprenorphine-based medications.

Key API manufacturers include:

Shin Poong Pharmaceutical Co., Ltd. (South Korea): A significant producer with established manufacturing capabilities. They are a known supplier to global pharmaceutical companies.
ABF (Active-Bio Pharmaceutical Co., Ltd.) (South Korea): Another established player in the South Korean API market, producing buprenorphine API.
Beijing Pharma & Bio-Tech Co., Ltd. (China): A major Chinese API manufacturer with a substantial capacity for various pharmaceutical ingredients, including buprenorphine.
Shandong Xinhua Pharmaceutical Co., Ltd. (China): A large, state-owned pharmaceutical company in China, also recognized as a supplier of buprenorphine API.
Hubei Biocause Pharmaceutical Co., Ltd. (China): A notable Chinese manufacturer producing a range of APIs, with buprenorphine being one of them.
Aurobindo Pharma (India): While primarily known for finished dosage forms, Aurobindo also has API manufacturing capabilities and is a potential source for buprenorphine API.
Dr. Reddy's Laboratories (India): Similar to Aurobindo, Dr. Reddy's is a major pharmaceutical player with API manufacturing divisions that may produce buprenorphine.

These manufacturers are subject to inspections by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to ensure compliance with Good Manufacturing Practices (GMP).

What are the Regulatory Requirements for Buprenorphine API?

The production and sourcing of buprenorphine API are subject to stringent regulatory controls due to its classification as a Schedule III controlled substance in the United States and similar classifications internationally.

Key regulatory aspects include:

DEA Registration: Facilities manufacturing, distributing, or importing buprenorphine API in the U.S. must be registered with the Drug Enforcement Administration (DEA) and adhere to quota requirements.
FDA GMP Compliance: API manufacturers must comply with FDA's Current Good Manufacturing Practices (cGMP) regulations (21 CFR Parts 210 and 211). This involves rigorous quality control, documentation, and facility standards.
Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies like the FDA. These confidential documents provide detailed information about the manufacturing process, facilities, and quality controls of the API. Pharmaceutical companies reference these DMFs in their drug product applications.
International Narcotics Control Board (INCB) Oversight: Buprenorphine is listed in Schedule III of the United Nations Single Convention on Narcotic Drugs, 1961. International trade is monitored by the INCB to prevent diversion and ensure legitimate medical use. Manufacturers and importers must comply with international quota and reporting requirements.
ICH Guidelines: Manufacturers often adhere to International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines, particularly ICH Q7 for GMP for APIs, ensuring global quality standards.
Import/Export Controls: Strict controls govern the import and export of buprenorphine API, requiring specific permits and adherence to national drug control laws.

API suppliers must provide Certificates of Analysis (CoAs) with each batch, detailing purity, impurity profiles, and other critical quality attributes, which must meet pharmacopoeial standards (e.g., USP, EP).

What are the Market Dynamics and Trends in Buprenorphine API Sourcing?

The buprenorphine API market is influenced by several factors, including the increasing demand for opioid use disorder (OUD) treatments and the evolving regulatory landscape.

Key market dynamics and trends:

Growing Demand for OUD Treatments: The global opioid crisis has led to a significant increase in the demand for buprenorphine-based medications for OUD treatment. This trend directly drives demand for buprenorphine API.
Supply Chain Concentration: The limited number of primary API manufacturers creates potential supply chain vulnerabilities. Disruptions at any of these key sites can impact global availability.
Price Sensitivity: While quality and regulatory compliance are paramount, pricing remains a significant factor for pharmaceutical companies seeking to produce cost-effective generic buprenorphine products.
Geopolitical Factors: Trade policies, tariffs, and geopolitical stability in regions where API is manufactured can affect supply costs and reliability.
Quality and Compliance Focus: Regulatory scrutiny on API quality and cGMP compliance is intensifying. Companies are increasingly prioritizing suppliers with robust quality systems and a proven regulatory track record.
Emergence of New Suppliers: While the market is concentrated, there is ongoing effort by some pharmaceutical ingredient manufacturers to gain FDA approval and enter the buprenorphine API space, potentially increasing competition and diversifying the supply base over time.
Intellectual Property Landscape: While the patent for the original buprenorphine molecule has long expired, patents related to specific formulations, delivery systems, or novel polymorphs can still influence market entry and competition for finished products, indirectly impacting API demand.
Vertical Integration: Some large pharmaceutical companies may engage in backward integration to secure their API supply, either by developing their own API manufacturing capabilities or through strategic partnerships and acquisitions.

The market is characterized by a need for reliable, high-quality API from GMP-compliant facilities that can meet stringent international regulatory standards and DEA quotas.

What are the Challenges in Sourcing Buprenorphine API?

Sourcing buprenorphine API presents several challenges for pharmaceutical manufacturers, stemming from its controlled substance status, complex regulatory environment, and market structure.

Key challenges include:

DEA Quota Allocation: Obtaining sufficient DEA manufacturing and import quotas for buprenorphine API in the United States is a significant hurdle. Quotas are allocated annually and are based on estimates of legitimate medical, scientific, research, and industrial needs. Applicants must demonstrate a clear need and have a strong justification.
Stringent Regulatory Compliance: Meeting and maintaining cGMP compliance, as well as complying with DEA regulations and international drug control treaties, requires substantial investment in quality systems, documentation, and personnel training. Any lapse in compliance can lead to product recalls, import alerts, or manufacturing shutdowns.
Limited Supplier Pool: The relatively small number of established buprenorphine API manufacturers means that pharmaceutical companies have fewer options for sourcing. This can lead to increased reliance on a few key suppliers and potential supply chain risks.
Quality Assurance and Impurity Profiling: Ensuring consistent API quality, including controlling critical impurities and polymorphic forms, is essential for finished drug product efficacy and safety. Thorough vendor qualification and ongoing quality oversight are critical.
Lead Times and Inventory Management: Production lead times for APIs, especially those subject to strict regulatory controls, can be lengthy. Effective inventory management and forecasting are necessary to avoid stockouts, particularly for essential medicines.
Cost and Price Volatility: While generic competition exists, the cost of API production, driven by regulatory compliance and raw material sourcing, can be substantial. Price volatility can impact the profitability of generic buprenorphine products.
Security and Diversion Prevention: Robust security measures are required at manufacturing and distribution sites to prevent diversion of buprenorphine API, which is a controlled substance with potential for misuse.

Addressing these challenges requires a deep understanding of the regulatory framework, a rigorous vendor selection process, and proactive supply chain management strategies.

What is the Outlook for Buprenorphine API Sourcing?

The outlook for buprenorphine API sourcing is characterized by continued high demand driven by public health initiatives and evolving treatment paradigms, alongside persistent regulatory rigor and a focus on supply chain resilience.

Key elements of the outlook include:

Sustained Demand Growth: The ongoing recognition of buprenorphine as a cornerstone treatment for OUD is expected to maintain and likely increase demand for API. Expansion of access to OUD treatment services globally will further bolster this trend.
Regulatory Scrutiny to Persist: Regulatory bodies will continue to enforce strict cGMP standards and controlled substance regulations. This will favor API manufacturers with strong compliance records and robust quality management systems.
Focus on Supply Chain Security and Diversification: Pharmaceutical companies will increasingly prioritize supply chain security, seeking to mitigate risks associated with reliance on a limited number of suppliers. This may lead to greater interest in qualifying secondary suppliers and potentially exploring API manufacturing in new geographies, provided they can meet regulatory hurdles.
Potential for New Entrants: While challenging, the significant market demand may incentivize new API manufacturers to invest in the complex regulatory and manufacturing infrastructure required to enter the buprenorphine API market, potentially increasing competition over the long term.
Innovation in Delivery Systems: While not directly impacting bulk API sourcing, innovations in buprenorphine delivery systems (e.g., long-acting injectables) could influence the specific types and quantities of API required, and may involve proprietary API forms or processes.
Impact of Policy Changes: Government policies aimed at increasing OUD treatment access, such as expanded insurance coverage or reduced prescribing restrictions for buprenorphine, will directly impact API demand.

Manufacturers and pharmaceutical companies will need to navigate a complex interplay of increasing demand, stringent regulatory oversight, and the imperative for supply chain stability.

Key Takeaways

Buprenorphine API manufacturing is concentrated among a few key global producers, primarily in South Korea and China.
Stringent regulatory requirements, including DEA registration, cGMP compliance, and international controlled substance conventions, govern API production and distribution.
The growing demand for opioid use disorder treatments is the primary driver for buprenorphine API market growth.
Challenges in sourcing include DEA quota limitations, rigorous compliance demands, a concentrated supplier base, and the need for robust quality assurance.
The future outlook suggests sustained demand, continued regulatory stringency, and an increasing focus on supply chain resilience and potential diversification.

Frequently Asked Questions

What is the primary regulatory body overseeing buprenorphine API in the United States? The U.S. Drug Enforcement Administration (DEA) is the primary body overseeing controlled substances, including buprenorphine API, in the United States. The Food and Drug Administration (FDA) regulates its quality and manufacturing under cGMP.
Are there any non-Asian manufacturers of buprenorphine API that are FDA-approved? While the majority of large-scale buprenorphine API production is concentrated in Asia, the regulatory status of specific manufacturers can change. Pharmaceutical companies must verify the current FDA approval status and GMP compliance of any potential API supplier.
How does the DEA quota system impact the availability of buprenorphine API for generic manufacturers? The DEA quota system directly limits the total amount of buprenorphine API that can be manufactured or imported into the U.S. each year. Generic manufacturers must apply for and be granted a portion of this quota to produce or import their API, which can create a bottleneck and influence supply availability.
What are the typical lead times for sourcing bulk buprenorphine API from established manufacturers? Lead times for bulk buprenorphine API can vary significantly but typically range from 3 to 9 months from order placement to delivery, depending on the manufacturer's production schedule, current inventory, regulatory batch release timelines, and logistics.
Can a pharmaceutical company import buprenorphine API into the U.S. without a specific import quota from the DEA? No, any import of buprenorphine API into the United States requires a specific import permit and adherence to the DEA's quota system for controlled substances.

Citations

[1] U.S. Drug Enforcement Administration. (n.d.). Controlled Substances Act. Retrieved from [Official DEA Website] (Specific URL would depend on current DEA site structure). [2] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) Regulations. Retrieved from [Official FDA Website] (Specific URL would depend on current FDA site structure). [3] International Narcotics Control Board. (n.d.). The Blue List. Retrieved from [Official INCB Website] (Specific URL would depend on current INCB site structure). [4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. Retrieved from [Official ICH Website]. [5] Shin Poong Pharmaceutical Co., Ltd. Company Website and Publicly Available Information. (Various Dates). [6] ABF (Active-Bio Pharmaceutical Co., Ltd.). Company Website and Publicly Available Information. (Various Dates). [7] Beijing Pharma & Bio-Tech Co., Ltd. Company Website and Publicly Available Information. (Various Dates). [8] Shandong Xinhua Pharmaceutical Co., Ltd. Company Website and Publicly Available Information. (Various Dates). [9] Hubei Biocause Pharmaceutical Co., Ltd. Company Website and Publicly Available Information. (Various Dates). [10] Aurobindo Pharma Limited. Company Website and Publicly Available Information. (Various Dates). [11] Dr. Reddy's Laboratories Ltd. Company Website and Publicly Available Information. (Various Dates).

Bulk Pharmaceutical API Sources for BUPRENORPHINE